News

Priority Health will cover Pulmonx’s Zephyr Endobronchial Valve device as a non-surgical treatment option for severe emphysema, a severe form of chronic obstructive pulmonary disease (COPD). The insurer’s new coverage policy is specific to the device marketed by Pulmonx. With this Priority Health decision, some 30 million U.S. residents with…

The use of electronic cigarettes, more commonly known as vaping, triggers cellular responses in the lungs similar to those elicited by smoking tobacco cigarettes, which may place e-cigarette users at risk of developing chronic lung diseases, a study says. Results from the study, “Chronic E-Cigarette Use Increases Neutrophil Elastase…

Kali-Extracts has launched a dedicated website for its cannabis-based  therapy candidate, RespRX, for chronic obstructive pulmonary disease (COPD) and related disorders. The company announced that as it moves toward the goal of federal approval of RespRX, its website will be updated regularly with information about the applications’ status,…

The triple combination therapy Breztri Aerosphere has successfully achieved its primary goal of reducing the rate of exacerbations — bouts of breathlessness — in people with chronic obstructive pulmonary disease (COPD) in the ongoing ETHOS trial, AstraZeneca announced.

Patients with chronic obstructive pulmonary disease (COPD) who are experiencing severe exacerbations should receive noninvasive ventilation, regardless of factors such as older age, low body mass index (BMI), left heart dysfunction, and abnormal levels of gases in the blood, a study suggests. Researchers in the study found that these…

Medical device company Adherium and informatics company Summatix are teaming up to help clinicians provide the best possible care for people with asthma and chronic obstructive pulmonary disease (COPD). Through this partnership, Adherium will gain access to Summatix’s regulated data platform…

Nuvaira, a medical device company, announced the upcoming publication of several scientific studies detailing the findings of clinical trials that assessed the safety and effectiveness of its Targeted Lung Denervation (TLD) therapy in patients with chronic obstructive pulmonary disease (COPD). Nuvaira’s proprietary TLD therapy works to disrupt pulmonary…

Air pollution can increase the risk of emphysema among people who have never smoked, a recent study has found. The study, titled “Association Between Long-term Exposure to Ambient Air Pollution and Change in Quantitatively Assessed Emphysema and Lung Function,” was published in the Journal of the…

Olympus‘ Spiration Valve System (SVS), a device that can be inserted into a patient’s airways to redirect air from diseased regions of the lungs and toward its healthier parts, improves respiration in people with severe emphysema, a clinical trial found. Its results were reported in the study, “…

Verona Pharma released additional results of a Phase 2 trial demonstrating that maintenance treatment with its dry powder inhaler (DPI) formulation of ensifentrine (RPL554) is safe, and significantly improves lung function in people with moderate to severe chronic obstructive pulmonary disease (COPD). The trial met all its primary…